High patient safety and revascularization efficacy.
For the successful prevention and treatment of coronary restenosis.
Restore demonstrates an unparalleled product finish, which retains Paclitaxel in its balloon surface matrix coating. A premature debonding of the Paclitaxel during catheter manipulation and the risk of unintentional cath lab contamination is thereby eliminated.
SAFEPAX. with the unsurpassed non-crystalline coating and no PTX particulates protect from micro- embolization.
RESTORE ‘SAFEPAX’ technology utilizes the clinically important, stable amorphous PTX drug-coating. RESTORE ‘SAFEPAX’ coating is a step beyond contemporary first and second generation DCB coatings which had to compromise on vulnerable balloon coating mixtures out of a high water soluble drug excipient with relatively large PTX crystals.
Microscopy of the LEGFLOW DCB balloon surface
showing no visible PTX particulates
Minimizing the risk of micro-embolization.
RESTORE DCB ‘SAFEPAX’ technology provides maximum protection from downstream effects to minimize the risk potential of miocardial vascular changes. The biological ‘SAFEPAX’ drug release matrix avoids the side effects of plasticizer or contrast media drug excipients. Coronary artery treatment requires the highest degree of patient safety. The protection from necrosis in arterial tissue to minimize the risk potential of late coroanry aneurysm, and minimizing the risk of micro embolization to avoid myocardial damage, caused by vascular changes.